LCD L38985: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Palmetto GBA
Policy LCD-L38985 · Oncology
New MolDX requires billing team review.
Code intelligence
Z15.01 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code Z15.01.
Elevated code riskView ICD-10 detail
Signal breakdown
6 shown · 6 total in platform
Risk: Elevated
0
Critical
0%
2
High
33%
4
Routine
67%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
High
LCD L39007: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Noridian
Policy LCD-L39007 · Oncology
New LCD for prostate cancer risk-stratification impacts billing.
LCD L37608: MDS FISH — CGS
Policy LCD-L37608 · Clinical Laboratory
New LCD for MDS FISH impacts billing compliance.
LCD L38972: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer — Noridian
Policy LCD-L38972 · Oncology
New LCD affects billing for inherited cancer tests.
LCD L38351: MolDX: Repeat Germline Testing — Noridian
Policy LCD-L38351 · Oncology
New guidelines for repeat germline testing could impact reimbursements.
LCD L38353: MolDX: Repeat Germline Testing — Noridian
Policy LCD-L38353 · Clinical Laboratory
New LCD on germline testing impacts billing practices.
Audit documentation
Building an audit file that includes Z15.01?
The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Oncology audit pack — $349One-time purchase · not a subscription